Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 7/20 | 0.34 |
| ▸ | DRD1 | P21728 | 7/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | F3 | P13726 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11171087 | 0.75 | TDP1 (0.35) | DRD2DRD1TDP1L3MBTL1F3 | |
| SCHEMBL11160749 | 0.73 | DRD2 (0.35) | DRD2DRD1 | |
| Fumaric Acid SCHEMBL11169441 | 0.72 | SMN1; SMN2 (0.41) | DRD2DRD1TDP1L3MBTL1SMN1; SMN2 | |
| Fumaric Acid SCHEMBL11169435 | 0.72 | SMN1; SMN2 (0.41) | DRD2DRD1TDP1L3MBTL1SMN1; SMN2 | |
| SCHEMBL11171000 | 0.70 | DRD1 (0.38) | DRD2DRD1TDP1L3MBTL1TSHR | |
| SCHEMBL9826524 | 0.65 | MAOA (0.62) | DRD1TDP1L3MBTL1TSHR | |
| SCHEMBL5900986 | 0.62 | MEN1 (0.40) | ESR1TDP1 | |
| SCHEMBL9548521 | 0.60 | ADRA2A (0.59) | TDP1L3MBTL1 | |
| SCHEMBL9593768 | 0.60 | TNFSF11 (0.44) | ESR1TDP1TSHRRAB9ASMN1; SMN2 | |
| SCHEMBL16715040 | 0.59 | PGR (0.49) | ESR1TSHRRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0080012-A1 | 6-Chloro-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine, its acid addition salts and its use as an intermediate | SMITHKLINE BECKMAN CORPORATION (US) | 1983-06-01 | — | — | EP | disclosed |
| EP-0007070-B1 | 2,3,4,5-TETRAHYDRO-1H-3-BENZAZEPINES, PROCESS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS HAVING DOPAMINE RECEPTOR BLOCKING ACTIVITY | SMITHKLINE BECKMAN CORPORATION (US) | 1983-01-19 | — | — | EP | disclosed |
| US-4265890-A | ANTIPSYCHOTIC, ANTIEMETICS | SMITHKLINE CORPORATION (US) | 1981-05-05 | — | — | US | disclosed |
| EP-0007070-A1 | 2,3,4,5-Tetrahydro-1H-3-Benzazepines, process for their production and pharmaceutical compositions having dopamine receptor blocking activity | SMITHKLINE BECKMAN CORPORATION (US) | 1980-01-23 | — | — | EP | disclosed |